Hemodynamic Effects of Once-daily Tadalafil in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant ⍺1-Adrenergic Antagonist Therapy: Results of a Multicenter Randomized, Double-Blind, Placebo-controlled Trial - 01/04/12
Reprint requests: Suzanne R. Klise, Lilly Research Laboratories, Eli Lilly, 839 South Delaware Street, Indianapolis, IN 46225Résumé |
Objective |
To investigate the safety of daily coadministration of ⍺-blockers with tadalafil 5 mg in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. The standard-of-care medical therapy for moderate to severe symptoms of benign prostatic hyperplasia is ⍺1-adrenergic antagonist (⍺-blocker) therapy.
Methods |
Men aged ≥ 45 years receiving stable ⍺-blocker therapy were evaluated for eligibility before a 2-week single-blind, placebo lead-in period. Subsequently, 318 men were randomized to tadalafil 5 mg or placebo once daily for 12 weeks. Enrollment was monitored to ensure inclusion of men ≥75 years old and men taking nonuroselective ⍺-blockers. The primary objective was to compare the proportion of men reporting treatment-emergent dizziness between the 2 treatment groups. Orthostatic vital signs, general safety, and the International Prostate Symptom Score were also assessed.
Results |
The proportion of patients who reported treatment-emergent dizziness was not significantly different between the 2 treatment groups (tadalafil 7.0%; placebo 5.7%; P = .403). No difference between treatment groups was observed with respect to patients meeting the criteria for a positive orthostatic test (30 per treatment group, P = 1.00). The incidence of discontinuations was low among both treatment groups.
Conclusion |
Recognizing the limitations of the present study, the changes in the hemodynamic signs and symptoms were similar for the tadalafil and placebo groups in men with benign prostatic hyperplasia receiving concomitant ⍺-blocker therapy. However, consistent with the results of previous clinical pharmacology studies of healthy subjects, a trend was seen for increased hemodynamic signs and symptoms in men taking nonuroselective ⍺-blockers, most notably those taking doxazosin.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Support: This study was sponsored by Eli Lilly and Company (study code H6D-MC-LVHS). |
|
| Financial Disclosures: E. Goldfischer is a consultant/adviser for Astellas Pharmaceuticals, Boehringer Ingelheim, Eli Lilly and Company, Ferring Pharmaceuticals, Pfizer, and Watson Pharmaceuticals, and is an investigator for Allergan, Amgen, Astellas Pharmaceuticals, Biosante, Bioniche, Boehringer Ingelheim, Caris Lifesciences, Eli Lilly and Company, Ferring Pharmaceuticals, Healthever, Johnson & Johnson, Medtronic, Nymox, Pfizer, Predictive Biosciences, Spectrum, Takeda, Veridex, Warner Chilcott, Watson Pharmaceuticals, and Wilex; W. R. Clark is a consultant/adviser and investigator for Eli Lilly and Company; J. J. Kowalczyk is a consultant/adviser and investigator for Eli Lilly and Company; N. Dgetluck is an employee of i3 Statprobe; and E. Brady, S. R. Klise, and M. A. Shane are employees and minor shareholders of Eli Lilly and Company. |
Vol 79 - N° 4
P. 875-882 - avril 2012 Retour au numéro
Article précédent
- Thulium Laser Versus Holmium Laser Transurethral Enucleation of the Prostate: 18-Month Follow-up Data of a Single Center
- Fengbo Zhang, Qiang Shao, Thomas R.W. Herrmann, Ye Tian, Yuhai Zhang
- Relationship Between Procalcitonin Levels and Presence of Vesicoureteral Reflux During First Febrile Urinary Tract Infection in Children
- Ilke Ozahi Ipek, Rabia Gonul Sezer, Evrim Senkal, Abdulkadir Bozaykut
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?